Cimetidine Hydrochloride and Selegiline Hydrochloride

• Generic Name: cimetidine
• Dosage Forms: n.a.
• Other Brand Names: Tagamet HB, Tagamet

Short-term treatment of active duodenal ulcer (endoscopically or radiographically confirmed).

Maintainence of healing and reduction in recurrence of duodenal ulcer.

Pathologic GI Hypersecretory Conditions

Long-term treatment of Zollinger-Ellison syndrome, multiple endocrine adenomas, systemic mastocytosis.

Gastric Ulcer

Short-term treatment of active benign gastric ulcer.

Gastroesophageal Reflux (GERD)

Short-term treatment of erosive esophagitis (endoscopically diagnosed) in patients with GERD.

Treatment of symptomatic GERD.

Self-medication as initial therapy to achieve acid suppression, control symptoms, and prevent complications of less severe symptomatic GERD.

Upper GI Bleeding

Prevention of upper GI bleeding resulting from stress-related mucosal damage (erosive esophagitis, stress ulcers) in critically ill patients.

Treatment of upper GI bleeding secondary to hepatic failure, esophagitis, duodenal or gastric ulcers when hemorrhage is not caused by major blood vessel erosion.

Heartburn (pyrosis), Acid Indigestion (hyperchlorhydria), or Sour Stomach

Short-term self-medication for relief of heartburn symptoms in adults and adolescents ≥12 years of age.

Short-term self-medication for prevention of heartburn symptoms associated with acid indigestion (hyperchlorhydria) and sour stomach brought on by ingestion of certain foods and beverages in adults and children ≥12 years of age.

• Generic Name: selegiline
• Dosage Forms: n.a.
• Other Brand Names: Eldepryl, Zelapar, Emsam

Used as adjunctive therapy for symptomatic treatment of parkinsonian syndrome (e.g., parkinsonism, Parkinson disease [paralysis agitans]) in patients who exhibit a deteriorating response to levodopa/carbidopa; designated an orphan drug by FDA for this condition. Appears to be most beneficial when used during the early stages of the “wearing off” effect. Especially useful in improving “end-of-dose” motor fluctuations.

Has been used as monotherapy in patients with newly diagnosed parkinsonian syndrome. Because selegiline is well tolerated and possibly neuroprotective (i.e., reduces the rate of progression of parkinsonian syndrome ), some clinicians initiate therapy with selegiline in such patients, reserving levodopa or another agent (i.e., dopamine agonist) until manifestations become severe enough to warrant more aggressive therapy. However, the manufacturers state that there is no evidence from controlled studies indicating that selegiline provides benefit in the absence of concurrent levodopa therapy.

Has been used with equivocal results for the palliative treatment of mild to moderate dementia of the Alzheimer’s type (Alzheimer’s disease, presenile or senile dementia).